(Q49096071)

18 February 2018

title

Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. (English)

1 reference

18 February 2018

0 references

1 reference

Piet Ost

1

1 reference

18 February 2018

Karel Decaestecker

2

1 reference

18 February 2018

Bieke Lambert

3

1 reference

18 February 2018

Valérie Fonteyne

4

1 reference

18 February 2018

Louke Delrue

5

1 reference

18 February 2018

Nicolaas Lumen

6

1 reference

18 February 2018

Filip Ameye

7

1 reference

18 February 2018

Gert De Meerleer

8

1 reference

18 February 2018

publication date

1 February 2014

1 reference

18 February 2018

published in

The Prostate

1 reference

18 February 2018

volume

74

1 reference

18 February 2018

issue

3

1 reference

18 February 2018

page(s)

297-305

1 reference

18 February 2018

Natural history of progression after PSA elevation following radical prostatectomy

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

The number of pulmonary metastases: influence on practice and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Prognostic models for outcome following liver resection for colorectal cancer metastases: A systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

The natural history of noncastrate metastatic prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Is there a favorable subset of patients with prostate cancer who develop oligometastases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Stereotactic body radiotherapy for oligometastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

MicroRNA expression characterizes oligometastasis(es)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22750

21 January 2018

Identifiers

DOI

10.1002/PROS.22750

1 reference

18 February 2018

1 reference

18 February 2018